| ||||||||||||||||||
| ||||||||||||||||||
| acetaminophen dog |
How A Mere Male Can Lose 21 Kg In 8 Weeks Posted By : Around ten months ago, after thirty eight years of being a cigarette smoker, I finally realised what a disgusting habit it really is and decided it was time for me to quit. I decided that I was stronger than any habit or addiction and gave up cold turkey without any patches pills or anything else. The first week was extremely difficult but since then I have not even thought about cigarettes. By: Article Directory: http://www.articledashboard.com
Tony is a webmaster for several web sites and has written articles on financial and investment topics for many years. He can be contacted through his web site www.lose-more-weight.com or by email to tony@gr8riches.com
hemitartrate ambien zolpidem, adult adhd treatment non amphetamine, coreg heart pill, triamterene and hydrochlorothiazide, doea lexapro cause weight gain, long term side effects from paxil, ritalin in group batches of 3, vicodin no prescription picters, prescription zocor, generic zyban 16:44 - 2008-Mar-31 - comments {0} - post commentVermillion Announces Positive Results From Clinical Trial Of Ovarian Tumor Triage Test; Study Meets Primary EndpointsVermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, announced preliminary results from a clinical trial evaluating its Ovarian Tumor Triage Test. The study met its primary endpoints, demonstrating that the test successfully stratifies women with pelvic masses into high- and low-risk categories to determine whether the patient should be referred to a specialist prior to surgery. These results indicate that the use of this test could significantly increase the percentage of high-risk cases referred to the appropriate specialist for treatment, ultimately improving survival rates.(1)(2) Vermillion's novel ovarian biomarker panel ruled out malignancy with approximately 95 percent certainty or negative predictive value. Negative predictive value is the probability that the patient is free of disease based on diagnostic evaluation. The panel also showed approximately 90 percent sensitivity for detecting malignant ovarian tumors. The prospective clinical trial was one of the largest ever conducted and assessed more than 550 patients with a confirmed adnexal mass at 27 clinical trial sites in the United States. Vermilion plans to submit this in vitro diagnostic test to the U.S. Food and Drug Administration (FDA) for clearance. The Ovarian Tumor Triage Test provides information that may help improve outcomes for the hundreds of thousands of women in the United States who annually undergo surgery to remove a pelvic mass. While the vast majority of these tumors are benign, studies show that women with ovarian cancer who are initially operated on by a gynecologic oncologist have improved median and overall survival and have a better chance of being cured. Vermillion's ovarian tumor triage test utilizes a panel of biomarkers to help identify women at high risk of having cancer so that they can be referred directly to a gynecologic oncologist for their initial surgery. "The results from this clinical study hold promise for the large number of women diagnosed with an ovarian tumor each year," said Fred Ueland, M.D., principal investigator of the study and Associate Professor of Gynecologic Oncology at the University of Kentucky. "A test that informs women and their physicians of the risk of malignancy before surgery is an important advancement, and will help guide women to the appropriate specialist." "These statistically significant results represent a major milestone in bringing our Ovarian Tumor Triage Test one step closer to patients who so desperately need a way of determining their risk of having a cancerous mass," said Gail Page, President and CEO of Vermillion. "Additionally, the results further confirm the company's significant investment in and commitment to our ovarian cancer diagnostics program. We look forward to publicly sharing the full data after making our submission to the FDA." About Vermillion's Ovarian Cancer Diagnostic Program In addition to developing a diagnostic test designed to distinguish between benign and malignant pelvic masses, Vermillion has a broad program of ovarian cancer diagnostic tests in development. Studies are underway to detect early-stage ovarian cancer, predict prognosis and recurrence, and identify women considered at high-risk for the disease. Vermillion's comprehensive diagnostic development program is being conducted with several leading collaborators at The Johns Hopkins School of Medicine, The University of Texas M.D. Anderson Cancer Center, Rigshospitalet (Copenhagen), and the University of Kentucky. According to the American Cancer Society (ACS), approximately 22,430 new cases of ovarian cancer will be diagnosed this year, and 15,280 deaths will be reported as a result of the disease. When diagnosed at its earliest stages, ovarian cancer has a 5-year survival rate of 93 percent. However, only 19 percent of ovarian cancers are diagnosed before the tumor has spread outside the ovary. For late-stage disease, the 5-year survival rate falls to 18 percent. Ovarian cancer has up to a 90 percent cure rate following surgery and/or chemotherapy if detected in stage 1. About Vermillion Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com. Forward Looking Statements This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize its ovarian cancer diagnostic tests in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize ovarian cancer diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop ovarian cancer diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its ovarian cancer diagnostic products; (5) uncertainty of market acceptance of its ovarian cancer diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law. References (1) Giede et al, Gynecol Oncol, 2005 Nov;99(2):447-61. (2) Earle et al, JNCI, 2006 Feb 1;98(3):172-80. Vermillion, Inc. http://www.vermillion.com
cialis sublingual, order clomid no prescription, compazine benedryl ed treament migraine, paroxetine tablet 20 mg, pravachol bristol myers squibb, side effectsof tamoxifen, viagra suppositories heparin ivf, alaska vioxx heart attack lawyer, cheap yasmin, discontinuing zocor 20:11 - 2008-Mar-30 - comments {0} - post commentTreating Genital Herpes Does Not Reduce Risk Of HIV, Study SaysTreating genital herpes does not reduce the risk of contracting HIV, according to a study published Wednesday in the New England Journal of Medicine, Reuters reports. Herpes simplex virus-2 has been shown to increase the risk of HIV by as much as 69%, so many experts have been examining whether treating HSV-2 might reduce the risk of HIV. For the study, Deborah Watson-Jones of the London School of Hygiene and Tropical Medicine and colleagues enrolled 659 female workers ages 16 to 35 at recreational facilities in Tanzania (Fox, Reuters, 3/12). All the participants were HIV-negative and HSV-2-positive at the start of the study. Some of the women were given two daily pills of acyclovir, a drug that can suppress outbreaks of HSV-2, and some were given a placebo. The women visited mobile clinics every three months for 12 to 30 months (Watson-Jones et al., NEJM, 3/12). The study found that the women given two acyclovir pills daily were not less likely to contract HIV than women given placebos. "These data show no evidence that acyclovir as HSV-suppressive therapy decreases the incidence of infection with HIV," the researchers wrote. They noted that the given dose might not have been high enough to suppress herpes and that urine tests indicated many of the women were not taking the pills as prescribed. According to the researchers, an estimated 74%, 22% and 63% of new HIV cases among men, women and bar and hotel employees, respectively, in Tanzania are attributable to HSV-2. About 6.5% of people in Tanzania ages 15 to 49 are HIV-positive. HIV prevalence "reaches 40% in high risk groups, such as workers in bars and guesthouses, who may supplement their income by offering sex in return for money or gifts," the researchers added, noting that few use condoms (Reuters, 3/12). The study is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
pneumonia high dose amoxicillin, carisoprodol pi, depakote and booze, diflucan flonase, ibuprofen water retention danger, 33 levitra preis 47, 2 5 mg ramipril, soma troy pharmacy pa, tramadol over night, zocor vs kidney failure 12:47 - 2008-Mar-25 - comments {0} - post commentNecrotizing Fasciitis - Flesh-Eating Bacteria TreatmentSource: Free Articles from ArticlesFactory.com
azithromycin sale russia, celexa orgasm, cheap claritin d, didrex price, generic name imitrex, geberic prices for nexium, plavix pill identification, generic prilosec otc, safe alternatives for protonix, taking zoloft 12:42 - 2008-Mar-19 - comments {0} - post commentAustralia: Smoking And Blood Pressure Are DeadlySmoking and high blood pressure are a deadly combination that dramatically increase the risk of a blood vessel bursting inside the brain, Australian research shows. High blood pressure and smoking are known to increase the risk of heart diseases, but Sydney researchers have shown that the two have a stronger "synergistic effect" when both are present. A study by the George Institute for International Health in Sydney found that smokers with high blood pressure are significantly more likely to suffer from a hemorrhagic stroke, a type of "bleeding" stroke where a blood vessel bursts and bleeds in the brain, than non-smokers with blood pressure problems. Lead researcher Professor Koshi Nakamura said the revelation should encourage smokers to quit and deal with their blood pressure as well. "Since we found that these two risk factors have a synergistic effect, quitting smoking and lowering blood pressure will contribute more to preventing stroke than if this previously unreported interaction is ignored," Prof Nakamura said. A hemorrhagic stroke is especially debilitating as about half of sufferers die as a result of it, while many survivors are left with paralysis or other crippling effects. It was the only type of cardiovascular problem where researchers found this heightened risk. Smoking did not appear to exacerbate the impact of blood pressure on the risk of coronary heart disease or ischemic stroke, which was caused by a blood clot. The researchers believe smoking may damage blood vessels in the brain that are already weakened by high blood pressure. Weakened blood vessels are prone to rupture and bleeding and are therefore particularly susceptible to hemorrhagic stroke, Prof Nakamura said. The research, published by the American Heart Association, involved 563,144 people of mostly Asian descent. About 40% of all deaths in Australia each year are caused be heart, stroke and vascular diseases, which is more than any other disease group. http://www.ash.org.uk
buy aciphex from mexico, dose amoxycillin syrup 125 mg, buspirone withdrawal info, can you take cyclobenzaprine for hemorrhoids, taking hydrocodone while pregnant, nicotine reviews, phentermine no precription required, buy generic online soma, carisoprodol cheapest soma cube naproxeno carisoprodol, vicodin 7.5 mg 15:50 - 2008-Mar-18 - comments {0} - post comment |
Informationacetaminophen dog steroidRecent Posts• How A Mere Male Can Lose 21 Kg In 8 Weeks Posted By :• Vermillion Announces Positive Results From Clinical Trial Of Ovarian Tumor Triage Test; Study Meets Primary Endpoints • Treating Genital Herpes Does Not Reduce Risk Of HIV, Study Says • Necrotizing Fasciitis - Flesh-Eating Bacteria Treatment • Australia: Smoking And Blood Pressure Are Deadly Links• acetaminophen dextromethrophan doxylamine succinate• acetaminophen dextromethorphan hbr • acetaminophen diphenhydramine • acetaminophen diphenhydramine hc • acetaminophen diphenhydramine phenylephrine hc • acetaminophen doctor • acetaminophen dogs • acetaminophen dosage 24 hours • acetaminophen dosage chart • acetaminophen dosage for dogs • acetaminophen dosages • acetaminophen dose for infants • acetaminophen dose lethal • acetaminophen doseage • acetaminophen dosing chart • acetaminophen dosing reference • acetaminophen drug classification • acetaminophen drug information • acetaminophen drug taking test when • acetaminophen during pregnancy • acetaminophen effect on cholesterol • acetaminophen effects hydrocodone side • acetaminophen effects on liver • acetaminophen elixir • acetaminophen epilim • acetaminophen every 8 hrs for pain • acetaminophen extra • acetaminophen fact • acetaminophen fda patient information • acetaminophen fever in dogs • acetaminophen flu • acetaminophen for dogs • acetaminophen formation • acetaminophen found in cat food • acetaminophen free pain medication • acetaminophen functional groups • acetaminophen geometry • acetaminophen gout • acetaminophen guaifenesin phenylephrine hcl • acetaminophen hazard • acetaminophen hcl par tramadol • acetaminophen hepatotoxicity neurotransmitter net • acetaminophen highs • acetaminophen hplc analysis shimadzu • acetaminophen hydrocodone 500 5 • acetaminophen hydrocodone cause liver damage • acetaminophen hydrocodone lortab • acetaminophen ibuprofen • acetaminophen ibuprofen differences • acetaminophen ibuprofen interaction • acetaminophen ibuprofen mix single dose • acetaminophen ibuprofen together • acetaminophen ibuprofin • acetaminophen illagel • n cat food • acetaminophen in crabs • acetaminophen in dogs • acetaminophen in pet foods • acetaminophen indications • acetaminophen infant drops • acetaminophen integration risk • acetaminophen interaction with prozac • acetaminophen intoxication and sodium sulfate • acetaminophen isometheptene dichloralphenazone • acetaminophen kidney insufficiency • acetaminophen l405 • acetaminophen law suits kansas • acetaminophen lethal dose • acetaminophen level less than 10 • acetaminophen liver children • acetaminophen liver damage repair • acetaminophen liver enzymes hispanics elevations volunteers • acetaminophen liver failure acid kidney |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
